Should I buy or sell Silence Therapeutics stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Silence Therapeutics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" SLN shares. View SLN analyst ratings or view top-rated stocks .

What is Silence Therapeutics' stock price target for 2024?

4 equities research analysts have issued twelve-month target prices for Silence Therapeutics' shares. Their SLN share price targets range from $42.00 to $75.00. On average, they anticipate the company's stock price to reach $57.25 in the next year. This suggests a possible upside of 155.9% from the stock's current price. View analysts price targets for SLN or view top-rated stocks among Wall Street analysts .

How have SLN shares performed in 2024?

Silence Therapeutics' stock was trading at $17.37 at the beginning of the year. Since then, SLN stock has increased by 28.8% and is now trading at $22.37. View the best growth stocks for 2024 here .

Are investors shorting Silence Therapeutics?

Silence Therapeutics saw a increase in short interest in March. As of March 31st, there was short interest totaling 162,000 shares, an increase of 74.8% from the March 15th total of 92,700 shares. Based on an average daily volume of 241,700 shares, the short-interest ratio is presently 0.7 days. View Silence Therapeutics' Short Interest .

When is Silence Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 21st 2024. View our SLN earnings forecast .

How were Silence Therapeutics' earnings last quarter?

Silence Therapeutics plc (NASDAQ:SLN) posted its quarterly earnings data on Wednesday, March, 13th. The company reported ($0.47) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.25) by $0.22. The company had revenue of $2.61 million for the quarter, compared to the consensus estimate of $11.46 million. Silence Therapeutics had a negative net margin of 171.41% and a negative trailing twelve-month return on equity of 262.17%.

How do I buy shares of Silence Therapeutics?

Shares of SLN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:SLN

Silence Therapeutics (SLN) Stock Price, News & Analysis

→ SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad)

Free SLN Stock Alerts

$22.64

+0.62 (+2.82%)

(As of 04/19/2024 ET)

Compare

Today's Range: $21.76
▼
$23.18
50-Day Range: $20.66
▼
$26.25
52-Week Range: $4.55
▼
$27.72

Volume: 305,739 shs
Average Volume: 237,794 shs
Market Capitalization: $677.62 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $57.25

Get Silence Therapeutics alerts:

Silence Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 155.9% Upside
$57.25 Price Target
Short Interest: Healthy
0.54% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.38
Based on 3 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.38) to ($1.36) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.28 out of 5 stars

Medical Sector

511th out of 918 stocks

Pharmaceutical Preparations Industry

231st out of 417 stocks

3.5

Analyst's Opinion

Consensus Rating
Silence Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Silence Therapeutics has only been the subject of 4 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
0.54% of the outstanding shares of Silence Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
Silence Therapeutics has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Silence Therapeutics has recently increased by 74.76%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Silence Therapeutics does not currently pay a dividend.
Dividend Growth
Silence Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for SLN.

2.4

News and Social Media Coverage

News Sentiment
Silence Therapeutics has a news sentiment score of 0.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Silence Therapeutics this week, compared to 1 article on an average week.
Search Interest
9 people have searched for SLN on MarketBeat in the last 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Silence Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 2.95% of the stock of Silence Therapeutics is held by insiders.
Percentage Held by Institutions
98.73% of the stock of Silence Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Silence Therapeutics are expected to grow in the coming year, from ($1.38) to ($1.36) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Silence Therapeutics is -15.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Silence Therapeutics is -15.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Silence Therapeutics has a P/B Ratio of 31.51. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Crypto 101 Media

SHOCKING Crypto Leak…

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

Claim your free seat by clicking here now.

About Silence Therapeutics Stock (NASDAQ:SLN)

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver. The company develops Zerlasiran (SLN360), which is in phase 2 clinical trial for cardiovascular disease associated with elevated lipoprotein(a); and Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trials for the treatment of genetic hematological conditions, including polycythemia vera. It is also developing SLN-COMP-1 and SLN-COMP-2 for complement-mediated diseases; and SLN-HAN-1 and SLN-HAN-2. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; Hansoh Pharmaceutical Group Company Limited to develop siRNAs; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.

SLN Stock Price History

30 days | 90 days | 365 days | Advanced Chart

SLN Stock News Headlines

April 13, 2024 | yahoo.com

A youth's call to action on this Day of NO Silence

April 11, 2024 | investorplace.com

3 Biotech Stocks to Turn $5,000 Into $1 Million: April 2024

April 19, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

April 8, 2024 | businesswire.com

Silence Therapeutics Announces JAMA Publication of Additional Phase 1 Data for Zerlasiran in Subjects with Elevated Lipoprotein(a)

April 1, 2024 | yahoo.com

The Lady of Silence: The Mataviejitas Murders Streaming: Watch & Stream Online via Netflix

March 18, 2024 | investorplace.com

7 Biotech Stocks Ready to Ride the Sector's Resurgence

March 16, 2024 | finance.yahoo.com

Analysts Are Upgrading Silence Therapeutics plc (NASDAQ:SLN) After Its Latest Results

March 15, 2024 | seekingalpha.com

Silence Therapeutics plc (SLN) Q4 2023 Earnings Call Transcript

April 19, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

March 15, 2024 | finance.yahoo.com

Silence Therapeutics plc (NASDAQ:SLN) Q4 2023 Earnings Call Transcript

March 13, 2024 | yahoo.com

Local authors 'Break the Silence' with book anthology to share the stories of survivors

March 13, 2024 | sg.finance.yahoo.com

SingTel looking to sell significant Optus stake to Brookfield - source

March 13, 2024 | seekingalpha.com

Silence Therapeutics plc 2023 Q4 - Results - Earnings Call Presentation

March 13, 2024 | businesswire.com

Silence Therapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights

March 13, 2024 | businesswire.com

Silence Therapeutics Announces Positive Topline 36-Week Data from Ongoing Phase 2 Study of Zerlasiran in Patients with High Lipoprotein(a)

March 12, 2024 | markets.businessinsider.com

Silence Therapeutics earnings: here's what Wall Street expects

February 28, 2024 | finance.yahoo.com

Silence Therapeutics to Report Fourth Quarter and Full Year 2023 Results on March 13, 2024

February 28, 2024 | businesswire.com

Silence Therapeutics to Report Fourth Quarter and Full Year 2023 Results on March 13, 2024

February 24, 2024 | seekingalpha.com

Silence Therapeutics: Multiple 2024 Catalysts Make This mRNA Biotech Worth A Look

February 23, 2024 | businesswire.com

Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration Following the Initiation of Phase 1 Trial

February 22, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Silence Therapeutics (SLN) and Aurinia Pharmaceuticals (AUPH)

February 16, 2024 | finance.yahoo.com

Recursion Pharmaceuticals (RXRX) Surges 13.8%: Is This an Indication of Further Gains?

February 12, 2024 | investing.com

Silence Therapeutics PLC (SLN)

February 5, 2024 | finance.yahoo.com

Silence Therapeutics Announces Oversubscribed $120 Million Private Placement

November 27, 2023 | markets.businessinsider.com

Solid Financial Status and Promising Clinical Trial Results Drive Buy Rating for Silence Therapeutics

November 27, 2023 | finance.yahoo.com

Silence Therapeutics plc's (NASDAQ:SLN) 65% Price Boost Is Out Of Tune With Revenues

October 21, 2023 | msn.com

European Equities Traded in the US as American Depositary Receipts End Rough Week Lower Friday

See More Headlines

Receive SLN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Silence Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/13/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/21/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:SLN
CUSIP: N/A
CIK: 1479615
Web: www.silence-therapeutics.com
Phone: 44-0-20-3457-6900
Fax: N/A
Employees: 109
Year Founded: 1999

Price Target and Rating

Average Stock Price Target: $57.25
High Stock Price Target: $75.00
Low Stock Price Target: $42.00
Potential Upside/Downside: +152.9%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.46)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-53,820,000.00
Net Margins: -171.41%
Pretax Margin: -198.27%
Return on Equity: -262.17%
Return on Assets: -45.62%

Debt

Debt-to-Equity Ratio: 0.01
Current Ratio: 4.56
Quick Ratio: 4.56

Sales & Book Value

Annual Sales: $31.55 million
Price / Sales: 21.48
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.71 per share
Price / Book: 31.89

Miscellaneous

Outstanding Shares: 29,930,000
Free Float: 29,045,000
Market Cap: $677.62 million
Optionable: Not Optionable
Beta: 1.41

Social Links

5G Stocks: The Path Forward is Profitable

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

Mr. Craig A. Tooman M.B.A. (Age 59)
President, CEO & Executive Director
Comp: $1.46M
Ms. Rhonda L. Hellums (Age 51)
CFO & Secretary
Comp: $888.74k
Dr. Steven J. Romano M.D. (Age 65)
Head of Research & Development
Comp: $649.14k
Dr. Marie Wikstrom Lindholm Ph.D.
Chief Scientific Officer
Ms. Gem Gokmen Hopkins
Head of IR & Corporate Communications
Dr. Barbara A. Ruskin J.D. (Age 63)
Ph.D., Senior VP and Chief Intellectual Property & Innovation Officer
Dr. Eric Floyd M.B.A. (Age 61)
M.S., Ph.D., Senior Vice President of Regulatory Affairs & Quality Assurance
Mr. J.P. Gabriel
Chief Technical Operations Officer
Mr. Curtis Rambaran M.D.
Chief Medical Officer

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

SLN Stock Analysis - Frequently Asked Questions

Should I buy or sell Silence Therapeutics stock right now?: 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Silence Therapeutics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" SLN shares.
View SLN analyst ratings or view top-rated stocks.
What is Silence Therapeutics' stock price target for 2024?: 4 equities research analysts have issued twelve-month target prices for Silence Therapeutics' shares. Their SLN share price targets range from $42.00 to $75.00. On average, they anticipate the company's stock price to reach $57.25 in the next year. This suggests a possible upside of 155.9% from the stock's current price.
View analysts price targets for SLN or view top-rated stocks among Wall Street analysts.
How have SLN shares performed in 2024?: Silence Therapeutics' stock was trading at $17.37 at the beginning of the year. Since then, SLN stock has increased by 28.8% and is now trading at $22.37.
View the best growth stocks for 2024 here.
Are investors shorting Silence Therapeutics?: Silence Therapeutics saw a increase in short interest in March. As of March 31st, there was short interest totaling 162,000 shares, an increase of 74.8% from the March 15th total of 92,700 shares. Based on an average daily volume of 241,700 shares, the short-interest ratio is presently 0.7 days.
View Silence Therapeutics' Short Interest.

When is Silence Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 21st 2024.
View our SLN earnings forecast.
How were Silence Therapeutics' earnings last quarter?: Silence Therapeutics plc (NASDAQ:SLN) posted its quarterly earnings data on Wednesday, March, 13th. The company reported ($0.47) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.25) by $0.22. The company had revenue of $2.61 million for the quarter, compared to the consensus estimate of $11.46 million. Silence Therapeutics had a negative net margin of 171.41% and a negative trailing twelve-month return on equity of 262.17%.
How do I buy shares of Silence Therapeutics?: Shares of SLN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:SLN) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Silence Therapeutics (SLN) Stock Price, News & Analysis

Silence Therapeutics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

Company Ownership

Earnings and Valuation

About Silence Therapeutics Stock (NASDAQ:SLN)

SLN Stock Price History

SLN Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Institutional Ownership

SLN Stock Analysis - Frequently Asked Questions

Overall MarketRank^™